Has a known history of Hepatitis B or known active Hepatitis C virus infection.
Current known active infection with HIV, hepatitis B virus, or hepatitis C virus
Has known active Hepatitis B or known active Hepatitis C virus infection.
Subjects with known active human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infection
Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
Has a known history of hepatitis B or known active hepatitis C virus infection
Active hepatitis B and hepatitis C virus infection
Known active hepatitis A, B, or C virus infection
Known infection with human immunodeficiency virus or chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (anti hepatitis C virus positive)
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Positive Hepatitis C virus antibody (HCVAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Has known active hepatitis B or hepatitis C virus infection.
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Active HIV, hepatitis C virus, or hepatitis B virus infection(s)
Known active hepatitis A, B or C virus infection
Clinically active infection with hepatitis B or hepatitis C virus
Has evidence of active hepatitis B virus or hepatitis C virus
Active infection with hepatitis B or hepatitis C virus
Known hepatitis B virus, hepatitis C virus or HIV infection
Has known active infection with hepatitis B virus or hepatitis C virus
Must not have evidence of previous or current infection with hepatitis B virus
Known active hepatitis B virus hepatitis, or known active hepatitis C virus
Known active hepatitis C virus, or known active hepatitis B virus
Known hepatitis B virus, hepatitis C virus or HIV infection
Known active infection with HIV, hepatitis B virus, or hepatitis C virus
Patients with positive hepatitis C virus
Known hepatitis B virus, hepatitis C virus or HIV infection
Known HIV infection or active Hepatitis B or Hepatitis C virus infection
Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Known history of Hepatitis B or known active Hepatitis C virus.
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Active infection with hepatitis A, B or C virus
Known active hepatitis C virus, or known active hepatitis B virus
Clinically active infection with hepatitis B or hepatitis C virus
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
Known active infection with HIV or Hepatitis B or C virus
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Have active or uncontrolled clinically serious hepatitis B virus or hepatitis C virus infection.
Known infection with HIV or chronic infection with hepatitis B virus or hepatitis C virus
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known history of human immunodeficiency virus (HIV), active hepatitis C virus, active hepatitis B\r\nvirus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Active or latent virus disease (HIV, hepatitis B and hepatitis C)
Known active hepatitis C virus, or known active hepatitis B virus
Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus
Known clinically active infection with hepatitis B or hepatitis C virus
Patients with known active hepatitis B virus or hepatitis C virus acute or chronic infection
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known hepatitis B virus, hepatitis C virus or HIV infection
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
Documentation of hepatitis B virus and hepatitis C virus serology is required
Clinical evidence of active infection of any type, including hepatitis B or C virus
Known hepatitis B virus, hepatitis C virus or HIV infection;
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Known active Hepatitis B or Hepatitis C virus infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Active infection with Hepatitis B virus or Hepatitis C virus
Detectable Hepatitis C virus (indicative of active Hepatitis C)
Active hepatitis B and C virus infection
Known active infection with hepatitis A, B or C virus
Hepatitis B Virus, or Hepatitis C Virus infection (subjects with laboratory evidence of Hepatitis B Virus clearance may be enrolled).
Known active infection with HIV, Hepatitis B or C virus
Known active hepatitis B virus infection
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Currently known active infection with HIV, hepatitis B or C virus
Active hepatitis C virus
Active hepatitis B or C virus
Active infection with Hepatitis B virus or Hepatitis C virus
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, and entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.